TRUEBLUE
Trueblue, after having announced the integration of its Artificial Intelligence Relationship Management with Microsoft Dynamics 365 and Power Platform, officially launches on the market:
AiDEA is the new AI driven Omnichannel Customer Engagement suite. The foundation of the solution, represented by Artificial Intelligence , integrates and powers the operational and analytical functionalities based on Microsoft Dynamics 365 and Power Platform , for a holistic and integrated experience, with the goal of revolutionizing the working model of Pharma & Life Science markets, simplifying omni-channel engagement through intuitive and conversational interaction.
Two fundamental components guide the change, whose union had not yet materialized in the reference market: the concrete integration of Big Data in the perspective of Multichannel Management and the use of Artificial Intelligence functionalities and algorithms. The latter is an element that can no longer be postponed from an IT point of view, as it is necessary to drive Customer Engagement processes to satisfy company objectives from both a strategic and an operational point of view.
These elements require a structural change in the approach of organizations and tools, as a generic Customer Relationship Management system is no longer sufficient. It is in fact necessary to adopt specific Smart Omnichannel Customer Engagement solutions, fully enabled in terms of Artificial Intelligence, to have, in a quick, simple and intuitive way, precise indications about one's own customers.
As part of this transition in fact, Pharma companies such as Angelini Pharma , Alfasigma and others are taking this direction with strength and determination with the aim of innovating and achieving their business results faster.
"Artificial Intelligence represents a tremendous opportunity to increase our effectiveness and we want to provide this competitive advantage to our employees thanks to AiDEA" said Pierluigi Antonelli, CEO of Angelini Pharma "After a long and thorough analysis, we identified Trueblue and Microsoft as the best partners to advance our Customer Engagement capabilities by delivering an innovative digital CRM solution that transforms strategy into action.”
Trueblue , which has always been at the center of technological and digital innovation for the pharmaceutical industry, thanks to the integration with Microsoft introduces with AiDEA a new paradigm in which Artificial Intelligence is the backbone and key factor of the evolutionary process.
"Through this integration, Trueblue will help companies in the industry accelerate their growth and find new ways to drive Digital Innovation through a wide range of solutions that will enable them to simplify the use of AI in their daily activities," said Marco Bonesini CEO of Trueblue
“In today’s reality of accelerated digital transformation processes, pharma & life science companies rely on proactive solutions such as AIDEA, integrated with Dynamics 365 and Power Platform, to enable effective omnichannel strategies” said Elena Bonfiglioli, Managing Director, HealthCare and Life Sciences, EMEA Regional Lead.
Discover more About Trueblue
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005610/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release
This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where
Smartstream Introduces Agentic AI ‘Smart Agents’ for Investigations and Exceptions Handling4.12.2025 09:55:00 CET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the preview of Smart Agents for Investigations, a breakthrough in financial operations that brings augmented and autonomous exception handling to reconciliations and back-office processes. The new investigation agent combines domain-trained AI agents, workflow adoption, and embedded controls to triage, investigate, resolve, and learn from exceptions - reducing manual effort, accelerating time to resolution, and strengthening auditability. It will add a layer of intelligence on top of Smartstream’s current reconciliations and exceptions solutions. It understands the breaks context, adheres to customer playbooks and reaches out for missing information. It documents every step for audit and compliance, allowing analysts to focus on risk. Finally, it augments the analyst’s investigation with contextual information radically changing the user experience to review and a
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes4.12.2025 09:00:00 CET | Press release
The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for multiple new targets LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA™ platform to optimise NANOBODY® molecules for multiple new targets in the area of inflammation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204759388/en/ “We are truly excited abo
GoWit One: The Unified AI Operating System Set to Revolutionize Commerce & Retail Media4.12.2025 07:09:00 CET | Press release
WPP Turkey has been selected as a pilot partner to deploy GoWit One, cutting campaign setup time to 10 minutes. GoWit, a global AdTech leader in omnichannel Commerce and Retail Media, announced the launch of GoWit One, the unified AI operating system that brings automation, unification, and real-time intelligence into a single ad platform for agencies operating across multiple retailers, channels, and markets. By bringing these three elements into one dashboard, GoWit One addresses the industry's most critical bottleneck: operational inefficiency. The platform enables agencies to manage campaigns across multiple retailers, channels, and markets, reducing manual AdOps workflows by 98%, turning a process that used to take hours into as little as 10 minutes. Solving the “Fragmentation Crisis” Despite the explosive growth of Retail Media, the industry faces a significant hurdle. According to the IAB, 70% of the market still lacks end-to-end AI adoption. Media buyers are currently forced to
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings4.12.2025 07:00:00 CET | Press release
‘BBB’ long-term issuer credit rating from S&P Global RatingsPositive outlook, reflecting expected profitability improvement, ramp up of Nemluvio, and continued deleveraging and balance sheet improvementRecognition of Galderma’s science-based dermatology portfolio and global operations Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation. S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom